CRBP logo

CRBP
Corbus Pharmaceuticals Holdings Inc

21,435
Mkt Cap
$179.85M
Volume
252,204.00
52W High
$20.56
52W Low
$5.23
PE Ratio
-1.62
CRBP Fundamentals
Price
$9.71
Prev Close
$10.14
Open
$9.92
50D MA
$8.58
Beta
1.29
Avg. Volume
226,272.78
EPS (Annual)
-$5.90
P/B
1.16
Rev/Employee
$0.00
$53.90
Loading...
Loading...
News
all
press releases
Corbus Pharma Aligns With FDA On Registration Path For CRB-701 In HNSCC And Cervical Cancer
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage company, Tuesday announced that it broadly aligned with the FDA on the registration path for CRB-701, a highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical c...
Nasdaq News: Markets·13h ago
News Placeholder
More News
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving Average - Time to Sell?
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Pass Above 50 Day Moving Average - What's Next...
MarketBeat·14d ago
News Placeholder
HC Wainwright Issues Negative Forecast for CRBP Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Corbus Pharmaceuticals in a research...
MarketBeat·27d ago
News Placeholder
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·28d ago
News Placeholder
Research Analysts Offer Predictions for CRBP FY2030 Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals...
MarketBeat·28d ago
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Expected to Rise, Oppenheimer Analyst Says
Oppenheimer boosted their price target on shares of Corbus Pharmaceuticals from $53.00 to $57.00 and gave the company an "outperform" rating in a research report on Tuesday...
MarketBeat·28d ago
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Releases Quarterly Earnings Results
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) announced its quarterly earnings results on Monday. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, beating...
MarketBeat·30d ago
News Placeholder
Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Tuesday
Corbus Pharmaceuticals (NASDAQ:CRBP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...
MarketBeat·1mo ago
News Placeholder
Corbus Pharmaceuticals Touts Catalyst-Rich 2026 With CRB-701 and CRB-913 Data Readouts Ahead
Corbus Pharmaceuticals (NASDAQ:CRBP) outlined a catalyst-rich 2026 at Oppenheimer's 36th Annual Healthcare Conference, with Chief Executive Officer Yuval Cohen highlighting upcoming mid-year and...
MarketBeat·1mo ago
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Jefferies Financial Group
Jefferies Financial Group raised Corbus Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday...
MarketBeat·2mo ago
<
1
2
...
>

Latest CRBP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.